P&G India announces Rs 2000 Cr health manufacturing facility investment in Gujarat
To set up as an export hub in India
Procter & Gamble India will invest Rs 2000 crore to set up a new state-of-the-art personal healthcare manufacturing facility in Gujarat. The investment was announced by LV Vaidyanathan, CEO, P&G India, in a meeting with Bhupendra Patel, Chief Minister, Gujarat. The facility builds on top of P&G India’s existing manufacturing footprint of 8 plants across the country and expands the existing presence in Gujarat. P&G already operates a state-of-the-art manufacturing plant in Sanand, Ahmedabad, since 2015.
The new state-of-the-art manufacturing plant will produce products that are part of P&G’s global healthcare product portfolio, especially digestives. This facility will be operational over the next few years and is set to become an export hub for P&G globally, as it will help P&G India in serving consumers across the globe.
With this investment, P&G India will help create hundreds of direct and indirect jobs, thereby offering a significant boost to the local economy. The investment reflects upon P&G's continued focus on partnering in India’s growth journey, and its commitment to continuously evolve and transform its supply chain to best meet the needs of its consumers, customers, and community. Just over the last decade, P&G has invested over Rs 8200 crore/$ 1 billion through its operations in the country.
Bhupendra Patel, Chief Minister, Gujarat, said, “I congratulate P&G India for the newly commissioned project. This marks a new milestone in their journey in the state and the country. This manufacturing site will also be an export hub, and we welcome all the opportunities it unlocks for the local community. Gujarat and P&G India have had a longstanding association with their existing plant in Sanand, Ahmedabad. The expansion of their operations in our state is a testament to the immense potential, opportunities, and support Gujarat offers to the industry.”
LV Vaidyanathan, CEO, P&G India said, “At P&G, we are committed to partnering in India’s growth journey and have continued to operate as a force for growth and a force for good over the years. The new manufacturing facility in Gujarat is a testament to our belief in the immense growth potential that the country offers. We extend our gratitude to the Chief Minister of Gujarat, for the inspiring discussion, which highlighted our mutual commitment to the growth of the state, the country, and its people. With the new state-of-the-art facility, our objective is to transform India into an export hub for P&G globally. It also marks a significant milestone in our journey, enabling us to extend our local footprint and further elevate our capacity to deliver
exceptional innovations to consumers."
The new facility is situated across a 50,000 sqm area in Sanand, Gujarat. It will use state-of-the-art technology to manufacture superior products in the digestive wellness space and is designed to be fully automated based on the modern concept of ‘Industry 4.0’. This concept employs futuristic technology including the latest vision systems for quality checks, robotic equipment for material movement and operator cockpits to name a few. Further, the plant will act as an enabler towards our ambition of driving equality and inclusion across our
shopfloors as it enables anyone irrespective of their gender or orientation, to fulfil any required task on the operations. The investment is being planned through an unlisted private company and does not impact any of the listed public companies of the P&G group in India.
Through its flagship CSR programme P&G Shiksha, P&G India has been providing access to a holistic education to lesser privileged children across the country by strengthening educational infrastructure, remediating learning gaps, and empowering marginalised groups through education. In the state, the efforts under P&G Shiksha initiatives are positively impacting nearly 2.5 lakh children.
Recommended
Dozee Shravan to remotely monitor patients
October 8, 2024
WHO adds an HPV vaccine for single-dose use
October 8, 2024